SecBot SecBot
SECBOTREPLAY Home › Report › ARQT

ARQT · Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4M…

Arcutis Biotherapeutics, Inc. · PRESS-RELEASE filed May 6, 2026 at 16:00 ET

At the news

MIXEDIMPACT 5/10

PRESS-RELEASE filed May 6, 2026 at 16:00 ET

Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4M (+65% YoY), beating consensus of $103.7M, but EPS of -$0.09 missed consensus of -$0.06. Full-year 2026 revenue guidance of $480M-$495M was maintained. The stock may face pressure from the EPS miss despite strong revenue growth and positive operating cash flow.

  • Q1 2026 net product revenue $105.4M, +65% YoY vs $63.8M, beating $103.7M consensus
  • GAAP EPS -$0.09 vs consensus -$0.06 (miss of 50%)
  • Full-year 2026 revenue guidance maintained at $480M-$495M
  • Positive operating cash flow of $2.2M in Q1 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access